What is Nuvation Bio's 12 months or more?

Nuvation Bio (NUVB) reported 12 months or more of $0 in Q4 2025.

How has Nuvation Bio's 12 months or more changed year-over-year?

Nuvation Bio's 12 months or more decreased by 100.0% year-over-year, from $55.01M to $0.

Tango TherapeuticsTNGX

——

Nektar TherapeuticsNKTR

——

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Market cap$2.25B+150%

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

What is Nuvation Bio's 12 months or more?: Nuvation Bio (NUVB) reported 12 months or more of $0 in Q4 2025.
How has Nuvation Bio's 12 months or more changed year-over-year?: Nuvation Bio's 12 months or more decreased by 100.0% year-over-year, from $55.01M to $0.